Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Gene Silencing/Gene Editing » Aventis Researcher Discusses Company s Use Of siRNAs to Improve Cancer Drug Therapy

Aventis Researcher Discusses Company s Use Of siRNAs to Improve Cancer Drug Therapy

Nov 07, 2003
Premium

Although RNAi’s future as a therapeutic is uncertain, the technology has been wildly successful as a means for determining gene function. Just about every major drugmaker uses RNAi to support its drug discovery and target validation efforts, and Aventis is no exception.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Lander Nominated for Science Advisor

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

What's It Called?

Nature News writes that scientists are trying to figure out how to name the new strains of SARS-CoV-2 that are emerging.

Twin COVID-19 Studies

The New York Times reports that researchers are studying identical twins who had COVID-19 to understand the influence of genetics on disease severity.

PNAS Papers on Positive Epistasis in Cystic Fibrosis, Tiger Rattlesnake Genome, More

In PNAS this week: epistasis affecting cystic fibrosis, Tiger rattlesnake genome gives venom insight, and more.

Jan
26
Featured Webinar

Panel Discussion: Genotyping by Sequencing for Novel SNP Discovery with Less Common Genomes

Sponsored by
LGC, Biosearch Technologies

Reduced representation next-generation sequencing (NGS) methods are driving understanding of both physical and structural variation in all species.

Feb
18
Featured Webinar

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

What's Popular?

In Gene Silencing/Gene Editing

  1. Mammoth Biosciences Taking Lead Role in DARPA-Funded Development of Pathogen Detection Tech

    Premium

  2. DARPA Awards $36.7M to Six Organizations for Gene Editing-Based Dx, Biosurveillance Tech

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.